Lundbeck exec joins Asarina Pharma as CMO

9 July 2018

A small Swedish pharmaceutical company has taken another step towards being the first company in the world to launch a targeted treatment for premenstrual dysphoric disorder (PMDD) - the most debilitating form of premenstrual syndrome (PMS).

Dr Märta Segerdahl, with over 20 years’ experience in pain medicine, including menstrual migraine, has been appointed chief medical officer of Asarina Pharma.

“There are very few drugs out there for the worst type of PMS,” says Dr Segerdahl. “And the ones we have are only moderately effective for some patients. I’ve been in this field for years, very few companies have come as far as Asarina have - with a project in the clinical development phase and a safe therapy built on an extremely clever scientific concept,” she added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK